drugset / Trial / NCT05941442

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

NCT05941442

Phase 2 Terminated 80 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams \[mg\] twice daily \[BID\]) compared with placebo in participants with panic disorder.

Timeline

Start
2023-07-31
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule 25 mg Oral

Indications